Publication details
The cost study of treating mCRC with bevacizumab plus chemotherapy in the real clinical practice in the Czech Republic
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Conference abstract |
| Citation | |
| Description | Bevacizumab, a humanized monoclonal IgG antibody against the vascular endothelial growth factor (VEGF), is reimbursed in the Czech Republic in combination with chemotherapy for the first-line treatment of patients with metastatic colorectal cancer (mCRC). However, its high cost is a potentially limiting factor. |